AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19298364 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group Ib and IIb)
Number of subjects: 222
Study 17897485 — intervention group
Group type: EXPERIMENTAL
Intervention: dTpa
Number of subjects: 460
Study 17897485 — intervention group
Group type: EXPERIMENTAL
Intervention: dTpa-IPV
Number of subjects: 460
Study 17897485 — intervention group
Group type: COMPARATOR
Intervention: Td (control)
Number of subjects: 460
Study 14991325 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic group (n=8)
Number of subjects: 15
Study 14991325 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=7)
Number of subjects: 15
Study 14991325 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study 11253854 — intervention group
Group type: EXPERIMENTAL
Intervention: SCVK 100, 300, or 400 microg administered depending on INR value
Number of subjects: 139
Study 11253854 — intervention group
Group type: COMPARATOR
Intervention: Withholding warfarin
Number of subjects: 139
Study 9554680 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with chlorthalidone and atenolol (or reserpine)
Number of subjects: 4736
Study 7914260 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued exclusive breastfeeding to 6 months (EBF)
Number of subjects: 141
Study 7914260 — intervention group
Group type: EXPERIMENTAL
Intervention: Introduction of complementary foods at 4 months with ad libitum nursing from 4-6 months (SF)
Number of subjects: 141
Study 7914260 — intervention group
Group type: EXPERIMENTAL
Intervention: Introduction of complementary foods at 4 months, with maintenance of baseline nursing frequency from 4-6 months (SF-M)
Number of subjects: 141
Study 7914260 — intervention group
Group type: COMPARATOR
Intervention: Control group (EBF)
Number of subjects: 141
Study 3056086 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention via walkman
Number of subjects: 90
Study 3056086 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalamonal 1-2 ml i.m.
Number of subjects: 90
Study 3056086 — intervention group
Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 90
Study 31782377 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline intake of 930 mg/d
Number of subjects: 71
Study 31782377 — intervention group
Group type: COMPARATOR
Intervention: Choline intake of 480 mg/d
Number of subjects: 71
Study 31782377 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproductive state (non-pregnant)
Number of subjects: 71
Study 31782377 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproductive state (pregnant)
Number of subjects: 71
Study 31782377 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproductive state (lactating)
Number of subjects: 71
Study 31782377 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproductive state (pregnant vs lactating)
Number of subjects: 71
Study 28844293 — intervention group
Group type: EXPERIMENTAL
Intervention: Maropitant (1 mg kg−1, n = 12)
Number of subjects: 24
Study 28844293 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.1 mL kg−1, n = 12)
Number of subjects: 24
Study 25877989 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH-MLR 20 mg
Number of subjects: 221
Study 25877989 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH-MLR 40 mg
Number of subjects: 221
Study 25877989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 25877989 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH-MLR (various doses during open-label phase)
Number of subjects: 221
Study 25877989 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH-MLR (various doses)
Number of subjects: 221
Study 23522432 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (LC) diet (initial carbohydrate intake 20 g/d, with a 10 g increase weekly)
Number of subjects: 50
Study 23522432 — intervention group
Group type: COMPARATOR
Intervention: Energy-restricted (ER) diet (carbohydrate intake 156-205 g/d, ER to 5021 or 6276 kJ/d, 35% average energy reduction)
Number of subjects: 50
Study 21406143 — intervention group
Group type: EXPERIMENTAL
Intervention: Root ZX
Number of subjects: 50
Study 21406143 — intervention group
Group type: EXPERIMENTAL
Intervention: ProPex
Number of subjects: 50
Study 21406143 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiography
Number of subjects: 50
Study 19916807 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom severity measured with the Early Signs and Symptoms Scale
Number of subjects: 40
Study 19916807 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress measured with the Hassles Scale
Number of subjects: 40
Study 18254505 — intervention group
Group type: EXPERIMENTAL
Intervention: No Bite (a spray formulation with diethyl toluamide, 2 methyl 2,4 pentondiol and pthalic ester acids)
Number of subjects: 0
Study 18254505 — intervention group
Group type: EXPERIMENTAL
Intervention: X‐pel (a petroleum jelly formulation containing diethyl toluamide (DEET) and dimethyl phthalate)
Number of subjects: 0
Study 18254505 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero Bite (a blend of microcrystalline waxes, mineral oils, natural flavours, Olibanum oil, Eucalyptus oil, Geranium oil, Citronella oil and Isopropyl myristrate)
Number of subjects: 0
Study 14996104 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept 7.5 mg administered once weekly for 12 weeks
Number of subjects: 553
Study 14996104 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept in course 1 and placebo in course 2
Number of subjects: 553
Study 14996104 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept
Number of subjects: 553
Study 14996104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 553
Study 11300610 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 100-150 microg
Number of subjects: 14
Study 11300610 — intervention group
Group type: COMPARATOR
Intervention: Baseline (without clonidine)
Number of subjects: 14
Study 11300610 — intervention group
Group type: COMPARATOR
Intervention: Comparison of GFR changes between BG<10 mmol/L and BG>15 mmol/L
Number of subjects: 14
Study 9043962 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg once a day)
Number of subjects: 12
Study 9043962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8159601 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin sodium 250 mg (250 mg/5 ml)
Number of subjects: 12
Study 8159601 — intervention group
Group type: COMPARATOR
Intervention: Fosphenytoin 375 mg (375 mg/5 ml)
Number of subjects: 12
Study 3063076 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemonucleolysis
Number of subjects: 151
Study 3063076 — intervention group
Group type: COMPARATOR
Intervention: Surgery (Discectomy)
Number of subjects: 151
Study 31302249 — intervention group
Group type: EXPERIMENTAL
Intervention: GGA 400 mg/day
Number of subjects: 26
Study 31302249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 30625106 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP monitoring (NPM)
Number of subjects: 100
Study 30625106 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy
Number of subjects: 100
Study 30625106 — intervention group
Group type: COMPARATOR
Intervention: Control group (NT-proBNP <1400 pg/ml)
Number of subjects: 100
Study 30625106 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncompliant patients
Number of subjects: 100
Study 30625106 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 concentration
Number of subjects: 100
Study 28712212 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 154
Study 28712212 — intervention group
Group type: COMPARATOR
Intervention: Levetiracetam
Number of subjects: 154
Study 25701345 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoid-rich blueberry drink
Number of subjects: 14
Study 25701345 — intervention group
Group type: COMPARATOR
Intervention: Matched vehicle (control)
Number of subjects: 14
Study 23194023 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones 60 mg and Lactobacillus sporogenes 1 billion spores
Number of subjects: 130
Study 23194023 — intervention group
Group type: COMPARATOR
Intervention: Calcium and vitamin D₃
Number of subjects: 130
Study 21092178 — intervention group
Group type: EXPERIMENTAL
Intervention: Philani intervention (home visits by Mentor Mothers for one year)
Number of subjects: 788
Study 21092178 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 788
Study 18326331 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan monotherapy (angiotensin receptor blocker)
Number of subjects: 0
Study 18326331 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment with an ARB
Number of subjects: 0
Study 17008704 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (fluorouracil 350 mg/m2/d during 5 days with leucovorin, 45 Gy in 25 fractions over 5 weeks)
Number of subjects: 733
Study 17008704 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiotherapy (45 Gy in 25 fractions over 5 weeks)
Number of subjects: 733
Study 12871405 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1500 mg daily
Number of subjects: 31
Study 12871405 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 3000 mg daily
Number of subjects: 31
Study 12871405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 10068849 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for 7 days
Number of subjects: 98
Study 10068849 — intervention group
Group type: COMPARATOR
Intervention: Heart failure patients (NYHA class III or IV)
Number of subjects: 98
Study 10068849 — intervention group
Group type: COMPARATOR
Intervention: Heart failure patients
Number of subjects: 98
Study 10068849 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (N=26)
Number of subjects: 98
Study 8595511 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitors
Number of subjects: 0
Study 8595511 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of protease inhibitors with reverse transcriptase inhibitors
Number of subjects: 0
Study 1700203 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg of enoximone orally
Number of subjects: 10
Study 843178 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (0.5 mg/kg)
Number of subjects: 0
Study 31347166 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas luteola + Bacillus sp. (T2)
Number of subjects: 100
Study 31347166 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas luteola + Enterobacter sp. (T1)
Number of subjects: 100
Study 31347166 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas luteola + Acinetobacter sp. (T3)
Number of subjects: 100
Study 31347166 — intervention group
Group type: COMPARATOR
Intervention: Control (T4)
Number of subjects: 100
Study 27483990 — intervention group
Group type: EXPERIMENTAL
Intervention: DYN (dynamic warm-up: 4 × 4 crank-cycles)
Number of subjects: 6
Study 27483990 — intervention group
Group type: EXPERIMENTAL
Intervention: ISO (isometric warm-up: 4 × 5-sec maximal voluntary contraction)
Number of subjects: 6
Study 27483990 — intervention group
Group type: COMPARATOR
Intervention: CON (control: rest)
Number of subjects: 6
Study 25659029 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (six weekly doses)
Number of subjects: 48
Study 25659029 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (eight weekly doses)
Number of subjects: 48
Study 25659029 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (eight doses, two clustered doses over 3 weeks)
Number of subjects: 48
Study 25659029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 24528783 — intervention group
Group type: EXPERIMENTAL
Intervention: BASIC intervention (10,000 steps/day, no guidance on intensity), n=50
Number of subjects: 120
Study 24528783 — intervention group
Group type: EXPERIMENTAL
Intervention: ENHANCED intervention (10,000 steps/day and at least 30 minutes in moderate intensity), n=50
Number of subjects: 120
Study 24528783 — intervention group
Group type: COMPARATOR
Intervention: Control group, n=20
Number of subjects: 120
Study 24528783 — intervention group
Group type: EXPERIMENTAL
Intervention: BASIC intervention
Number of subjects: 120
Study 24528783 — intervention group
Group type: EXPERIMENTAL
Intervention: ENHANCED intervention
Number of subjects: 120
Study 24528783 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 22814766 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro Emotional Technique® (NET) - two 20-minute sessions
Number of subjects: 45
Study 22814766 — intervention group
Group type: COMPARATOR
Intervention: Stretching instruction - two 20-minute sessions (active control group)
Number of subjects: 45
Study 22814766 — intervention group
Group type: COMPARATOR
Intervention: No intervention or instruction (passive control group)
Number of subjects: 45
Study 19570307 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplantation
Number of subjects: 72
Study 19570307 — intervention group
Group type: COMPARATOR
Intervention: Dialysis without kidney transplant
Number of subjects: 72
Study 19570307 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 72
Study 18093312 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive 'pen and paper' intervention designed to increase intentions to perform three target behaviours (finding out what the patient knows, using explicit terminology, exploring what the diagnosis means).
Number of subjects: 0
Study 18093312 — intervention group
Group type: EXPERIMENTAL
Intervention: Persuasive communication targeting subjective norm.
Number of subjects: 0
Study 18093312 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural modelling and graded tasks targeting self-efficacy.
Number of subjects: 0
Study 18093312 — intervention group
Group type: EXPERIMENTAL
Intervention: Persuasive communication targeting attitude towards explicit terminology.
Number of subjects: 0
Study 18093312 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural modelling targeting perceived behavioural control.
Number of subjects: 0
Study 15083312 — intervention group
Group type: EXPERIMENTAL
Intervention: L. helveticus fermented milk
Number of subjects: 20
Study 15083312 — intervention group
Group type: EXPERIMENTAL
Intervention: L. helveticus derived peptides
Number of subjects: 20
Study 15083312 — intervention group
Group type: COMPARATOR
Intervention: Control milk
Number of subjects: 20
Study 15083312 — intervention group
Group type: COMPARATOR
Intervention: Control juice
Number of subjects: 20
Study 12133516 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/m2.d-1 of Ara-C administered by intravenous drip in 2 divided doses for two days (total dose 6 g/m2) + rhG-CSF at 300 microg.body(-1).d(-1) subcutaneously once a day until APBSC harvest.
Number of subjects: 22
Study 12133516 — intervention group
Group type: COMPARATOR
Intervention: 5 g/m2.d-1 of Ara-C administered by intravenous drip in 2 divided doses for two days (total dose 10 g/m2) + rhG-CSF at 300 microg.body(-1).d(-1) subcutaneously once a day until APBSC harvest.
Number of subjects: 22
Study 9718254 — intervention group
Group type: EXPERIMENTAL
Intervention: lamotrigine (300 mg p.o.)
Number of subjects: 12
Study 9718254 — intervention group
Group type: EXPERIMENTAL
Intervention: phenytoin (300 mg p.o.)
Number of subjects: 12
Study 9718254 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydrocodeine (90 mg p.o.)
Number of subjects: 12
Study 9718254 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 7862843 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.18 mg/kg)
Number of subjects: 48
Study 7862843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 3434168 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intercostal block with bupivacaine
Number of subjects: 39
Study 3434168 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated intercostal block
Number of subjects: 39
Study 3434168 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 39
Study 3434168 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine infusions
Number of subjects: 39
Study 3434168 — intervention group
Group type: COMPARATOR
Intervention: Control group (single dose of intercostal bupivacaine)
Number of subjects: 39
Study 3434168 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 39
Study 28591071 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular (IA) steroid injection (0.5 mL of 0.5% bupivacaine mixed with 10 mg dexamethasone)
Number of subjects: 40
Study 28591071 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic thoracic medial branch block (MBB) (0.5 mL of 0.5% bupivacaine mixed with 10 mg dexamethasone)
Number of subjects: 40
Study 27619779 — intervention group
Group type: EXPERIMENTAL
Intervention: 73.5 mg oxybutynin patch
Number of subjects: 579
Study 27619779 — intervention group
Group type: EXPERIMENTAL
Intervention: 105 mg oxybutynin patch
Number of subjects: 579
Study 27619779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 579
Study 24738786 — intervention group
Group type: EXPERIMENTAL
Intervention: Panasonic EW-DL90
Number of subjects: 84
Study 24738786 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 84
Study 22818117 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Event Multilevel Surgery (SEMLS)
Number of subjects: 19
Study 19937427 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 microg MK-7 in the form of Natto capsules
Number of subjects: 334
Study 19937427 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules containing olive oil
Number of subjects: 334
Study 18415823 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose theophylline
Number of subjects: 487
Study 18415823 — intervention group
Group type: COMPARATOR
Intervention: Montelukast
Number of subjects: 487
Study 18415823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study 18415823 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 487
Study 19661446 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mM ketorolac
Number of subjects: 13
Study 19661446 — intervention group
Group type: COMPARATOR
Intervention: 10 mM N(G)-nitro-l-arginine methyl ester (NOS-inhibited)
Number of subjects: 13
Study 19661446 — intervention group
Group type: COMPARATOR
Intervention: Combined NOS and COX inhibition
Number of subjects: 13
Study 19661446 — intervention group
Group type: COMPARATOR
Intervention: Control (Ringer)
Number of subjects: 13
Study 16400368 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Form (SF)
Number of subjects: 400
Study 16400368 — intervention group
Group type: COMPARATOR
Intervention: Traditional Medical Record (TMR)
Number of subjects: 400
Study 11596162 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO)
Number of subjects: 29
Study 11596162 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating positive expiratory pressure (OPEP)
Number of subjects: 29
Study 11596162 — intervention group
Group type: COMPARATOR
Intervention: Postural drainage, percussion, and vibration (PDPV)
Number of subjects: 29
Study 9470081 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective digestive decontamination (SDD) with oral non-absorbable antibiotics (polymyxin E, tobramycin and amphotericin B)
Number of subjects: 100
Study 9470081 — intervention group
Group type: COMPARATOR
Intervention: No administration (Control group)
Number of subjects: 100
Study 8204282 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril therapy in addition to acetylsalicylic acid (ASA) and isosorbide dinitrate (ISDNI)
Number of subjects: 0
Study 8204282 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) and isosorbide dinitrate (ISDNI)
Number of subjects: 0
Study 3673207 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified chick embryo cell culture rabies vaccine (PCECV)
Number of subjects: 177
Study 3673207 — intervention group
Group type: EXPERIMENTAL
Intervention: Human diploid cell strain rabies vaccine (HDCSV)
Number of subjects: 177
Study 3673207 — intervention group
Group type: COMPARATOR
Intervention: Intradermal (i.d.) vaccination with 0.1 ml
Number of subjects: 177
Study 3673207 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule of immunization on days 0, 28, and 56
Number of subjects: 177
Study 3673207 — intervention group
Group type: EXPERIMENTAL
Intervention: PCECV
Number of subjects: 177
Study 30878629 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 91
Study 30878629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 28228418 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg/day)
Number of subjects: 14
Study 28228418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 28920356 — intervention group
Group type: EXPERIMENTAL
Intervention: Choudongning (CDN) capsule
Number of subjects: 588
Study 28920356 — intervention group
Group type: COMPARATOR
Intervention: Tiapridal tablets
Number of subjects: 588
Study 28920356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study 25072396 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine
Number of subjects: 15000
Study 25072396 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15000
Study 23112428 — intervention group
Group type: EXPERIMENTAL
Intervention: Case Based Teaching (CBT)
Number of subjects: 179
Study 23112428 — intervention group
Group type: COMPARATOR
Intervention: Traditional Method of Teaching (TRD)
Number of subjects: 179
Study 19885408 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed handpiece without coolant
Number of subjects: 60
Study 19885408 — intervention group
Group type: COMPARATOR
Intervention: High-speed handpiece with coolant
Number of subjects: 60
Study 19885408 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-speed polishing without coolant
Number of subjects: 60
Study 19885408 — intervention group
Group type: COMPARATOR
Intervention: Low-speed polishing with coolant
Number of subjects: 60
Study 17565921 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous conivaptan 20 mg loading dose (day 1) + 40 mg/d continuous infusion (days 1-4)
Number of subjects: 0
Study 17565921 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous conivaptan 20 mg loading dose (day 1) + 80 mg/d continuous infusion (days 1-4)
Number of subjects: 0